The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile
Open accessAbstract
The CD40–CD40 ligand (CD40L) signaling axis plays an important role in immunological pathways. Consequently, this dyad is involved in chronic inflammatory diseases, including atherosclerosis. Inhibition of CD40L in apolipoprotein E (Apoe)–deficient (Apoe−/−) mice not only reduced atherosclerosis but also conferred a clinically favorable plaque phenotype that was low in inflammation and high in fibrosis. Blockade of CD40L may not be therapeutically feasible, as long-term inhibition will compromise systemic immune responses. Conceivably, more targeted intervention strategies in CD40 signaling will have less deleterious side effects. We report that deficiency in hematopoietic CD40 reduces atherosclerosis and induces features of plaque stability. To elucidate the role of CD40–tumor necrosis factor receptor-associated factor (TRAF) signaling in atherosclerosis, we examined disease progression in mice deficient in CD40 and its associated signaling intermediates. Absence of CD40-TRAF6 but not CD40-TRAF2/3/5 signaling abolishes atherosclerosis and confers plaque fibrosis in Apoe−/− mice. Mice with defective CD40-TRAF6 signaling display a reduced blood count of Ly6Chigh monocytes, an impaired recruitment of Ly6C+ monocytes to the arterial wall, and polarization of macrophages toward an antiinflammatory regulatory M2 signature. These data unveil a role for CD40–TRAF6, but not CD40–TRAF2/3/5, interactions in atherosclerosis and establish that targeting specific components of the CD40–CD40L pathway harbors the potential to achieve therapeutic effects in atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · cited 1×
“Vol. 207 No. 2 391-404 www.jem.org/cgi/doi/10.1084/jem.20091293 391 Atherosclerosis is a chronic inflammatory disease of the large arteries that involves multiple immuno logical processes (Hansson, 2005; Weber et al., 2008).”
BackgroundInfluentialAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
Alternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 2×
“4 c) in WT but not in CD40/ macrophages, indicating that absence of CD40 polarizes macrophages toward an M2 phenotype (Martinez et al., 2009).”
BackgroundTacke, F., Alvarez, D., Kaplan, T. J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28549 · Cited by 1,323
Cited by
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Macrophages in atherosclerosis: a dynamic balance
Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3520 · Cited by 2,559
Atherosclerosis: current pathogenesis and therapeutic options
Weber, C., & Noels, H. (2011) · Nature Medicine · doi:10.1038/nm.2538 · Cited by 2,203
Self-citationYang, J., Zhang, L., Yu, C., Yang, X.-F., & Wang, H. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-1 · Cited by 1,099
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,019
Self-citationHyperlipidemia-triggered neutrophilia promotes early atherosclerosis
Drechsler, M., Megens, R. T. A., van Zandvoort, M., Weber, C., & Soehnlein, O. (2010) · Circulation · doi:10.1161/circulationaha.110.961714 · Cited by 698
Self-citationInflammation and its Resolution as Determinants of Acute Coronary Syndromes
Libby, P., Tabas, I., Fredman, G., & Fisher, E. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302699 · Cited by 521
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I., & Tao, W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 518
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
Döring, Y., Manthey, H. D., Drechsler, M., Lievens, D., Megens, R. T. A., Soehnlein, O., Busch, M., Manca, M., Koenen, R. R., Pelisek, J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.046755 · Cited by 456
Self-citationWalsh, M. C., Lee, J., & Choi, Y. (2015) · Immunological Reviews · doi:10.1111/imr.12302 · Cited by 438
Anti-inflammatory therapies for atherosclerosis
Bäck, M., & Hansson, G. K. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.5 · Cited by 378
Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages
Baitsch, D., Bock, H. H., Engel, T., Telgmann, R., Müller-Tidow, C., Varga, G., Bot, M., Herz, J., Robenek, H., von Eckardstein, A., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.222745 · Cited by 358
Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis
Chen, P.-Y., Qin, L., Li, G., Wang, Z., Dahlman, J. E., Malagon-Lopez, J., Gujja, S., Cilfone, N. A., Kauffman, K. J., Sun, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0102-3 · Cited by 346
Self-citationPlatelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis
Lievens, D., Zernecke, A., Seijkens, T., Soehnlein, O., Beckers, L., Munnix, I. C. A., Wijnands, E., Goossens, P., van Kruchten, R., Thevissen, L., et al. (2010) · Blood · doi:10.1182/blood-2010-01-261206 · Cited by 301
Self-citationInflammation and immune system interactions in atherosclerosis
Legein, B., Temmerman, L., Biessen, E. A. L., & Lutgens, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1289-1 · Cited by 292
Self-citationHundelshausen, P. V., & Lievens, D. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-08-0592 · Cited by 271
Self-citationMolecular basis and therapeutic implications of CD40/CD40L immune checkpoint
Tang, T., Cheng, X., Truong, B., Sun, L., Yang, X., & Wang, H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107709 · Cited by 271
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
“Inhibition of CD40 signaling reduces atherosclerosis in mice,(125) and CD40-CD40L binding leads to recruitment of TRAFs (TNF receptor-associated factors) of which CD40-TRAF6 is involved in atherogenesis.(126) Smallmolecule inhibitors of CD40-TRAF6 have been developed that have the ability to reduce atherosclerosis and…”
BackgroundAdaptive Response of T and B Cells in Atherosclerosis
Ketelhuth, D. F. J., & Hansson, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306427 · Cited by 270
Do the Apoe −/− and Ldlr −/– Mice Yield the Same Insight on Atherogenesis?
Getz, G. S., & Reardon, C. A. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.306874 · Cited by 198
Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis
Seijkens, T. T. P., van Tiel, C. M., Kusters, P. J. H., Atzler, D., Soehnlein, O., Zarzycka, B., Aarts, S. A. B. M., Lameijer, M., Gijbels, M. J., Beckers, L., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.055 · Cited by 195
“CD40-TRAF2/3/5 interactions only play a minor role in these diseases, and are more required for CD40-associated immunity (12,17).”
InfluentialSelf-citationImmunotherapy for cardiovascular disease
Lutgens, E., Atzler, D., Döring, Y., Duchene, J., Steffens, S., & Weber, C. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz283 · Cited by 192
Self-citationMacrophage polarization in metabolic disorders: functions and regulation
Chinetti-Gbaguidi, G., & Staels, B. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834a77b4 · Cited by 175
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis
Kreuger, J., & Phillipson, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.2 · Cited by 160
Phenotypic modulation of macrophages in response to plaque lipids
Adamson, S., & Leitinger, N. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834a97e4 · Cited by 154
Metadata
- Authors
- Lutgens, E., Lievens, D., Beckers, L., Wijnands, E., Soehnlein, O., Zernecke, A., Seijkens, T., Engel, D., Cleutjens, J., Keller, A. M., Naik, S. H., Boon, L., Oufella, H. A., Mallat, Z., Ahonen, C. L., Noelle, R. J., de Winther, M. P., Daemen, M. J., Biessen, E. A., & Weber, C.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-01-25
- Volume
- 207
- Issue
- 2
- Pages
- 391-404
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2123723916
- Cited by
- 246
- References
- 6
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.